Esophagitis: A Novel Adverse Event of Crizotinib in a Patient with ALK-Positive Non– Small-Cell Lung Cancer Neeharika Srivastava, MD, Paul A. VanderLaan,

Slides:

Advertisements

Similar presentations

Evaluation of 18F-FDG PET-CT for Differentiation of Pulmonary Pathology in an Approach of Outpatient Fast Track Assessment Tjeerd S. Aukema, MD, Renato.

Advertisements

Volume 139, Issue 4, Pages (April 2011)

Malignant Triton Tumor of the Brachial Plexus Invading the Left Thoracic Inlet: A Rare Differential Diagnosis of Pancoast Tumor Jo Dartnell, BSc, MRCS,

Akos Varga-Szemes, MD, PhD, U. Joseph Schoepf, MD, Laura S

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,

Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.

Paraneoplastic Opsoclonus-Myoclonus Syndrome as a New and Single Manifestation of Relapsing Disease in a Patient with Small Cell Lung Cancer Ernest Nadal,

Y-L Chang, MD, C-T Wu, MD, Y-C Lee, MD, PhD

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient Jong Sik Lee, MD, Jae Young Hur, PhD,

Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation Andrea L.H. Arnett, MD, PhD, Kenneth.

Sclerosing Pneumocytoma with Lymph Node Metastasis

Exogenous Lipoid Pneumonia Mimicking Multifocal Bronchogenic Carcinoma

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael.

Zeynep Eroglu, MD, Jae Kim, MD, Sharon Wilczynski, MD, PhD, Warren A

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma Taylor M.

Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations Lynette M. Sholl, MD, Mizuki Nishino, MD, Saraswati.

Meta-Analysis of Positron Emission Tomographic and Computed Tomographic Imaging in Detecting Mediastinal Lymph Node Metastases in Nonsmall Cell Lung Cancer

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Novel Association of Elastofibroma with Aortic Stenosis: Report of a Case Report Interfering with a Thoracotomy Procedure and a Reassessment of Typical.

Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1

An Unusual Presentation of Malignant Pleural Mesothelioma

Pulmonary botryomycosis: A difficult diagnosis in the preoperative patient Russell Hodgson, MBBS, Shane A. Blackmore, MBBS, C. Peter Clarke, FRACS The.

Hibernoma: 18F FDG PET/CT Imaging

A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib Akihiro Tamiya,

Malignant Triton Tumor of the Brachial Plexus Invading the Left Thoracic Inlet: A Rare Differential Diagnosis of Pancoast Tumor Jo Dartnell, BSc, MRCS,

A Severe Photosensitivity Dermatitis Caused by Crizotinib

Multiple Pulmonary Chondroid Hamartoma

Cardiac Dysfunction Caused by Osimertinib

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

A New KIT Gene Mutation in Thymic Cancer and a Promising Response to Imatinib Sung Hee Lim, MD, Ji-Yun Lee, MD, Jong-Mu Sun, MD, PhD, Kyoung-Mee Kim,

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

The role of positron emission tomography for non-small cell lung cancer Albert J. Chang, MD, PhD, Farrokh Dehdashti, MD, Jeffrey D. Bradley, MD Practical.

Yasuo Miura, MD, PhD, Mitsuru Tsudo, MD, PhD Mayo Clinic Proceedings

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF ) in an ALK Translocation-Positive Patient with Non-small.

Arnaud Uguen, MD, PhD Journal of Thoracic Oncology

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Pulmonary Metastases from Cervical Adenocarcinoma Regress to a ‘Hole’ Lot of Nothing Michael Guandalini, MBBS (Hons), BPhty, Karin Steinke, MD, MS, PD,

Acute intramural hematoma of the aorta as a cause of positive fluorodeoxyglucose positron emission tomography/computed tomography Alex Ryan, MD, Barry.

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Axillary Mass and Hypercalcemia: The Value of a Physical Examination

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Daniel B. Costa, MD, PhD, Susumu Kobayashi, MD, PhD

Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy Yelena.

Insidious: Takayasu Arteritis

A Systematic Review of Restaging After Induction Therapy for Stage IIIa Lung Cancer: Prediction of Pathologic Stage Sara de Cabanyes Candela, MD, Frank.

Matthew Reichert, MD, Eric S. Bensadoun, MD

Nivolumab-Induced Granulomatous Inflammation of the Pleura

Spontaneous Pneumothorax and Lung Carcinoma: Should One Consider Synchronous Malignant Pleural Mesothelioma? Trevor A. Flood, MD, Harman S. Sekhon, MD,

A Rare Case of Endobronchial Amelanotic Melanoma

Nicholas W. Choong, MD, Robert S. Hellman, MD

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Pulmonary Atelectasis after Stereotactic Ablative Radiotherapy for a Central Lung Tumor Sashendra Senthi, MBChB, FRANZCR, Eric F Ullmann, MD, Suresh.

Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC Francesco Gelsomino, MD, Valentina.

Marianna Koczywas, MD, Mihaela C. Cristea, MD

Ethnic Differences in the Management of Lung Cancer in New Zealand

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

EBUS-TBNA for the Clarification of PET Positive Intra-Thoracic Lymph Nodes—an International Multi-Centre Experience Robert C. Rintoul, FRCP, PhD, Kurt.

Focal Cholesterol Granuloma in the Anterior Mediastinum: [18F]-Fluoro-2-Deoxy-D- Glucose-Positron Emission Tomography and Magnetic Resonance Imaging Findings

Successful Treatment with Pemetrexed in a Patient with Mucinous Bronchioloalveolar Carcinoma: Long-Term Response Duration with Mild Toxicity Chiyuki.

Lack of FDG Uptake in Small Cell Carcinoma Associated with ANNA-1 Positive Paraneoplastic Autonomic Neuropathy Matthew S. Block, MD, PhD, Robert Vassallo,

Super Scan Using Positron Emission Tomography in Lung Cancer Patients

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC- Positive and FISH-Negative ALK Jong-Mu Sun, MD, PhD, Yoon-La Choi,

Presentation transcript:

Esophagitis: A Novel Adverse Event of Crizotinib in a Patient with ALK-Positive Non– Small-Cell Lung Cancer Neeharika Srivastava, MD, Paul A. VanderLaan, MD, PhD, Ciaran P. Kelly, MD, Daniel B. Costa, MD, PhD Journal of Thoracic Oncology Volume 8, Issue 3, Pages e23-e24 (March 2013) DOI: 10.1097/JTO.0b013e31827e2451 Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 PET-CT images disclosing severe circumferential lower esophageal wall thickening associated with mild mural FDG avidity and associated luminal narrowing. A, PET image, (B) CT images, and (C), fused images. The arrow indicates the esophageal abnormality. PET, positron emission tomography, CT, computed tomography; FDG, fluorodeoxy-D-glucose. Journal of Thoracic Oncology 2013 8, e23-e24DOI: (10.1097/JTO.0b013e31827e2451) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Midesophagus mucosal biopsies (hematoxylin and eosin stain). Representative images taken at (A) 200× and (B) 400× magnification demonstrate active esophagitis with surface ulceration and fibrinopurulent exudate (blue arrows), and granulation tissue formation (black arrows). The predominantly neutrophilic infiltrate has admixed eosinophils. Stains for microorganisms were negative (not shown). Journal of Thoracic Oncology 2013 8, e23-e24DOI: (10.1097/JTO.0b013e31827e2451) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions